Rheumatology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - 2012 Annual European Congress of Rheumatology (EULAR)

Progress in Oral Biologics for Rheumatoid Arthritis

Berlin, Germany / June 6-9, 2012

Berlin - Oral therapies for rheumatoid arthritis that target very specific molecular steps in the inflammatory pathway have reached phase III trials. The data generated from these trials indicate that the anti-inflammatory activity of...

PRIORITY PRESS - Annual European Congress of Rheumatology (EULAR)

Potential Sequence of TNF Inhibitors in Rheumatoid Arthritis and Evidence for Staying in Class Before Switching Mechanisms

Berlin, Germany / June 6-9, 2012

Berlin - Approximately 30% of patients with rheumatoid arthritis (RA) treated with a tumour necrosis factor (TNF) inhibitor will not have an adequate response. However, inadequate response on one of these agents does not predict failure on...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the Annual Meeting of the Canadian Rheumatology Association

The Role of Biologics in Psoriatic Arthritis Disease Control

Victoria, British Columbia / March 28-31, 2012

Reviewed and edited by: Majed M. Khraishi, MB, BSc, FRCPCMedical Director (Rheumatology)Nexus Clinical ResearchClinical Professor of Medicine (Rheumatology)Memorial University of NewfoundlandSt. John’s, Newfoundland &...

PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology

Non-TNF Inhibitor Biologics: Expanding Opportunities for Rheumatoid Arthritis Control

Chicago, Illinois / November 5-9, 2011

Chicago - Led by TNF inhibitors, biologics addressing a variety of mediators of inflammation, including other cytokines, as well as enzymatic pathways in the inflammatory response, have demonstrated unprecedented rates of control in...

PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology

Novel Oral Inhibitors of Select Enzymatic Pathways in Rheumatoid Arthritis Inflammation

Chicago, Illinois / November 5-9, 2011

Chicago - Small-molecule inhibitors of enzymatic pathways that control inflammation in rheumatoid arthritis (RA) are advancing rapidly in clinical trials and are expected to generate the next major evolution in targeted therapy. The most...

MEDICAL FRONTIERS - 75th Annual Meeting of the American College of Rheumatology

Sequencing Biologic Therapeutic Strategies in Rheumatoid Diseases

Chicago, Illinois / November 5-9, 2011

Chicago - By preventing tissue damage caused by inflammation, TNF inhibitors are changing the natural history of joint diseases and other autoimmune processes. At the ACR 2011 meeting, substantial data and discussion were devoted to the...

PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology

Interleukin-1 Inhibitors in Specific Rheumatoid Diseases

Chicago, Illinois / November 5-9, 2011

Chicago - Small-molecule inhibitors of enzymatic pathways that control inflammation in rheumatoid arthritis (RA) are advancing rapidly in clinical trials and are expected to generate the next major evolution in targeted therapy. The most...

PRIORITY PRESS - 75th Annual Meeting of the American College of Rheumatology

Rapid Treatment Response in Rheumatoid Arthritis: A Valuable Indicator of Reduced Risk of Joint Damage

Chicago, Illinois / November 5-9, 2011

Chicago - Previously, tight, early control of rheumatoid arthritis has been associated with less disease activity and fewer symptoms when measured over 1 year. New data with biologics associate early control with a reduction in structural...

ABSTRACTS in PERSPECTIVE - based on presentations from the 12th Annual European Congress of Rheumatology (EULAR)

Complete Remission as a Therapeutic Goal in Rheumatoid Arthritis: Accelerating Research with Biologics and Through New Inflammatory Pathways

London, UK / May 25-28, 2011

EDITORIAL OVERVIEW: Alfred A. Cividino, MD, FRCPC Clinical Professor of Medicine, Division of Rheumatology, McMaster University, Hamilton, Ontario A gents highly targeted at key molecular steps in the inflammatory process have...

MEDICAL FRONTIERS - 12th Annual European Congress of Rheumatology (EULAR)

Expanding Research in Intracellular Signalling: Promising Data in Rheumatoid Arthritis with Small-molecule Inhibitors

London, UK / May 25-28, 2011

Chief Medical Editor: Dr. Léna Coïc, Montréal, Québec The biologic agents first introduced for the treatment of rheumatoid arthritis (RA) more than a decade ago have provided unprecedented control in patients...

PAGE 2 OF 7   1 2 3 4 5 6 7